Guangdong Hybribio Biotech Co.,Ltd. (300639.SZ)
CNY 5.1
(0.99%)
CNY 5.1
(0.99%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 631.43 Million CNY | -48.02% |
| 2022 | 1.1 Billion CNY | 57.94% |
| 2021 | 701.13 Million CNY | 35.33% |
| 2020 | 518.09 Million CNY | 18.44% |
| 2019 | 437.44 Million CNY | 19.05% |
| 2018 | 367.43 Million CNY | 24.29% |
| 2017 | 295.62 Million CNY | 14.67% |
| 2016 | 257.81 Million CNY | 12.58% |
| 2015 | 228.99 Million CNY | 48.15% |
| 2014 | 154.56 Million CNY | 35.37% |
| 2013 | 114.18 Million CNY | 32.49% |
| 2012 | 86.17 Million CNY | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 148.3 Million CNY | 20.4% |
| 2024 Q1 | 123.16 Million CNY | -46.45% |
| 2024 Q3 | 451.38 Million CNY | 192.98% |
| 2023 Q4 | 230.01 Million CNY | 55.66% |
| 2023 Q3 | 147.77 Million CNY | 15.69% |
| 2023 FY | 575.6 Million CNY | -48.02% |
| 2023 Q2 | 127.73 Million CNY | -21.54% |
| 2023 Q1 | 162.78 Million CNY | -46.65% |
| 2022 Q4 | 305.13 Million CNY | 33.6% |
| 2022 Q2 | 241.26 Million CNY | -27.46% |
| 2022 Q1 | 332.56 Million CNY | 78.87% |
| 2022 FY | 1.1 Billion CNY | 57.94% |
| 2022 Q3 | 228.39 Million CNY | -5.33% |
| 2021 Q4 | 185.92 Million CNY | 4.73% |
| 2021 Q2 | 167.61 Million CNY | -1.45% |
| 2021 Q3 | 177.52 Million CNY | 5.92% |
| 2021 FY | 701.13 Million CNY | 35.33% |
| 2021 Q1 | 170.07 Million CNY | -6.33% |
| 2020 FY | 518.09 Million CNY | 18.44% |
| 2020 Q3 | 131.36 Million CNY | 6.92% |
| 2020 Q1 | 82.28 Million CNY | -33.85% |
| 2020 Q4 | 181.57 Million CNY | 38.22% |
| 2020 Q2 | 122.86 Million CNY | 49.31% |
| 2019 Q2 | 100.72 Million CNY | 5.67% |
| 2019 Q4 | 124.39 Million CNY | 6.31% |
| 2019 Q1 | 95.31 Million CNY | -13.21% |
| 2019 FY | 437.44 Million CNY | 19.05% |
| 2019 Q3 | 117.01 Million CNY | 16.18% |
| 2018 Q1 | 74.97 Million CNY | -14.88% |
| 2018 FY | 367.43 Million CNY | 24.29% |
| 2018 Q4 | 109.83 Million CNY | 13.65% |
| 2018 Q3 | 96.64 Million CNY | 12.39% |
| 2018 Q2 | 85.98 Million CNY | 14.69% |
| 2017 FY | 295.62 Million CNY | 14.67% |
| 2017 Q3 | 74.84 Million CNY | 4.75% |
| 2017 Q4 | 88.07 Million CNY | 17.68% |
| 2017 Q1 | 61.25 Million CNY | -19.17% |
| 2017 Q2 | 71.45 Million CNY | 16.66% |
| 2016 Q3 | 62.62 Million CNY | 0.14% |
| 2016 FY | 257.81 Million CNY | 12.58% |
| 2016 Q2 | 62.53 Million CNY | 9.98% |
| 2016 Q1 | 56.86 Million CNY | 0.0% |
| 2016 Q4 | 75.78 Million CNY | 21.0% |
| 2015 FY | 228.99 Million CNY | 48.15% |
| 2014 FY | 154.56 Million CNY | 35.37% |
| 2013 FY | 114.18 Million CNY | 32.49% |
| 2012 FY | 86.17 Million CNY | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Dian Diagnostics Group Co.,Ltd. | 3.35 Billion CNY | 81.167% |
| Hangzhou Tigermed Consulting Co., Ltd. | 358.41 Million CNY | -76.174% |
| Dirui Industrial Co.,Ltd. | 387.16 Million CNY | -63.093% |
| Beijing Strong Biotechnologies, Inc. | 702.74 Million CNY | 10.147% |
| Medicalsystem Biotechnology Co., Ltd. | 562.06 Million CNY | -12.343% |
| Maccura Biotechnology Co.Ltd | 1.18 Billion CNY | 46.507% |
| Guangzhou Wondfo Biotech Co.,Ltd | 1.17 Billion CNY | 46.278% |
| BGI Genomics Co., Ltd. | 1.93 Billion CNY | 67.439% |
| Amoy Diagnostics Co., Ltd. | 574.96 Million CNY | -9.822% |
| Shanghai Labway Clinical Laboratory Co., Ltd. | 479.96 Million CNY | -31.558% |